⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRMD News
CorMedix Inc.
Mundipharma宣布，其評估 REZZAYO ® （雷扎芬淨）用於預防異基因造血幹細胞移植患者侵襲性真菌病的III期ReSPECT試驗取得正面頂線結果
businesswire.com
CRMD
Form 8-K
sec.gov
CRMD
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO ® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients
businesswire.com
CRMD
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
globenewswire.com
CRMD
CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors
prnewswire.com
CRMD
CREATE Medicines to Showcase Multi-immune In Vivo CAR T, CAR NK, and All-RNA RetroT Platform at AACR 2026
prnewswire.com
CRMD
Airway Therapeutics nomme Joe Todisco, leader du secteur biopharmaceutique, à son conseil d'administration USA - Français USA - español USA - English
prnewswire.com
CRMD
AMRX
RNG
PRGS
Airway Therapeutics Appoints Biopharma Leader Joe Todisco to Board of Directors USA - English USA - español USA - Français
prnewswire.com
CRMD
AMRX
Airway Therapeutics beruft den führenden Biopharma-Experten Joe Todisco in den Vorstand USA - Deutsch USA - español USA - Français USA - English
prnewswire.com
CRMD
AMRX
Airway Therapeutics Appoints Biopharma Leader Joe Todisco to Board of Directors USA - English USA - Français USA - español USA - English
prnewswire.com
CRMD
AMRX
PRGS